Immunovaccine's DepoVax(TM) Technology Underpins New Experimental Therapy for Cervical, Head and Neck Cancers
08 Avril 2014 - 2:05PM
Marketwired
Immunovaccine's DepoVax(TM) Technology Underpins New Experimental
Therapy for Cervical, Head and Neck Cancers
IMV vaccine adjuvant technology of choice for Dana-Farber's
HPV-related cancer clinical trial
HALIFAX, NOVA SCOTIA--(Marketwired - Apr 8, 2014) -
Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX-VENTURE:IMV), a
clinical stage vaccine company, today announced that its DepoVax™
adjuvanting technology will underlie the design of a new cancer
vaccine trial that will be conducted by the Dana-Farber Cancer
Institute to treat cervical and head and neck cancer.
In a competitive process, Dana-Farber has been awarded a
research grant of $1.2 million for clinical evaluation of its
cancer vaccine. The grant from Stand Up To Cancer (SU2C) and the
Farrah Fawcett Foundation was awarded to a team of Dana-Farber
researchers in a ceremony last evening at the 2014 American
Association for Cancer Research (AACR) annual meeting.
The three-year grant will be used to fund a Phase I clinical
trial of the group's peptide cancer antigen formulated in DepoVax
in patients with HPV-related cervical and head and neck
cancers.
The grant was awarded based on a proposal highlighting the
potential of Dana-Farber's proposed cancer antigen identified by a
new mass spectrometry method termed Poisson detection MS and
Immunovaccine's DepoVax platform. The DepoVax data focused on
clinical trial results with DPX-Survivac, which demonstrated strong
immune response activity in cancer patients and the immune
enhancement observed with the immune modulating agent
cyclophosphamide. Dana-Farber's proposed Phase I study in
HPV-related cancers will use the same approach, formulating the
Institute's peptide-based vaccine in DepoVax and administering it
to patients in combination with cyclophosphamide.
"We believe that the grant committee was encouraged by novel
interdisciplinary science in conjunction with the powerful
immunogenicity data that Immunovaccine has collected to date with
our DPX-Survivac cancer vaccine candidate," stated Marc Mansour,
Ph.D., chief operating officer of Immunovaccine. "We are excited to
work with the talented team at Dana-Farber and add value to their
clinical program with our DepoVax technology. Our previous work
with DPX-Survivac gives us confidence that DepoVax has the
potential to induce strong immunological responses to their novel
antigen to enable the vaccine in the clinic."
The SU2C-Farrah Fawcett Foundation HPV Translational Research
Team Grant provides three years of funding for a multidisciplinary,
translational cancer research project that addresses critical
problems in HPV-related cancers and that can deliver near-term
patient benefit through investigation by a team of two expert
investigators. To be considered for the grant, research project
designs were required to include clear plans indicating how the
work will be translated into the clinic and deliver near-term
benefits to patients with HPV-related cancers. HPV infection causes
virtually all cervical cancers, and many anal, vaginal, vulvar,
penile, and oropharyngeal cancers.
About DepoVax™
DepoVax™ is a patented formulation that provides controlled and
prolonged exposure of antigens plus adjuvant to the immune system,
resulting in a strong, specific and sustained immune response with
the capability for single-dose effectiveness. The DepoVax platform
possesses impressive flexibility, allowing it to work with a broad
range of target antigens in various therapeutic applications. The
technology is also commercially scalable, with potential for years
of stability and ease of use in the clinic.
About DPX-Survivac
DPX-Survivac consists of survivin-based peptide antigens
formulated in the DepoVax™ adjuvanting platform. Survivin has been
recognized by the National Cancer Institute (NCI) as a promising
tumor-associated antigen (TAA) because of its therapeutic potential
and its cancer specificity. Survivin is broadly over-expressed in
solid tumors and blood cancers including ovarian, breast, colon and
lung cancers, among others. Survivin plays an essential role in
antagonizing apoptosis, supporting tumor-associated angiogenesis,
and promoting resistance to various anti-cancer therapies. Survivin
is also a prognostic factor for many cancers and it is found in
high percentage of cancer patients.
The DPX-Survivac vaccine is thought to work by eliciting a
cytotoxic T-cell immune response against cells presenting survivin
peptides on HLA class I molecules. This targeted therapy attempts
to use the immune system to actively search for tumor cells
expressing survivin and destroy them.
About Immunovaccine
Immunovaccine Inc. develops cancer immunotherapies and
infectious disease vaccines based on the Company's DepoVax™
platform, a patented formulation that provides controlled and
prolonged exposure of antigens and adjuvants to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine
therapy, DPX-Survivac, is expected to enter Phase II clinical
studies in 2014, in ovarian cancer and glioblastoma (brain cancer).
The Company is also advancing an infectious disease pipeline
including innovative vaccines for respiratory syncytial virus (RSV)
and anthrax.
Connect at www.imvaccine.com
This press release contains forward-looking information
under applicable securities law. All information that addresses
activities or developments that we expect to occur in the future,
is forward-looking information. Forward-looking statements are
based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Dr. Marc MansourChief Operating OfficerImmunovaccine Inc.T:
(902) 492-1819E: mmansour@imvaccine.comTim BronsVida Strategic
Partners (media)T: (415) 675-7402E: tbrons@vidasp.com
(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
(TSXV:IMV)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024